Table 2 Pre-matched and post-matched events by antiplatelet therapy.
Aspirin | Sarpogrelate | HR (95% CI) | |
|---|---|---|---|
NACE | |||
Pre-matched | 1676/9550 (17.6) | 141/1228 (11.5) | 1.02 (0.86–1.21) |
Post-matched | 226/1228 (18.4) | 141/1228 (11.5) | 0.71 (0.57–0.88) |
Efficacy endpoint* | |||
Pre-matched | 1511/9550 (15.8) | 132/1228 (10.8) | 1.08 (0.90–1.29) |
Post-matched | 202/1228 (16.5) | 132/1228 (10.8) | 0.75 (0.60–0.94) |
Overall bleeding | |||
Pre-matched | 165/9550 (1.7) | 9/1228 (0.7) | 0.42 (0.22–0.83) |
Post-matched | 24/1228 (2.0) | 9/1228 (0.7) | 0.38 (0.17–0.81) |
All-cause death | |||
Pre-matched | 1445/9550 (15.1) | 131/1228 (10.6) | 1.14 (0.95–1.36) |
Post-matched | 196/1228 (16.0) | 131/1228 (10.6) | 0.80 (0.63–1.00)† |
Myocardial infarction | |||
Pre-matched | 46/9550 (0.5) | 2/1228 (0.2) | 0.49 (0.12–2.01) |
Post-matched | 4/1228 (0.3) | 2/1228 (0.2) | 0.52 (0.09–3.07) |
Stroke | |||
Pre-matched | 100/9550 (1.1) | 4/1228 (0.3) | 0.46 (0.17–1.25) |
Post-matched | 14/1228 (1.1) | 4/1228 (0.3) | 0.32 (0.10–1.00)†† |
GI bleeding | |||
Pre-matched | 192/9550 (2.0) | 9/1228 (0.7) | 0.54 (0.28–1.06) |
Post-matched | 31/1228 (2.5) | 9/1228 (0.7) | 0.36 (0.17–0.77) |
ICH | |||
Pre-matched | 106/9550 (1.1) | 3/1228 (0.2) | 0.33 (0.10–1.04) |
Post-matched | 13/1228 (1.1) | 3/1228 (0.2) | 0.28 (0.08–1.00)††† |
Hospitalization d/t bleeding | |||
Pre-matched | 256/9149 (2.7) | 8/1195 (0.7) | 0.38 (0.19–0.78) |
Post-matched | 35/1195 (2.9) | 8/1195 (0.7) | 0.29 (0.13–0.62) |
Fatal bleeding | |||
Pre-matched | 55/9149 (0.6) | 1/1195 (0.1) | 0.24 (0.03–1.76) |
Post-matched | 5/1195 (0.4) | 1/1195 (0.1) | 0.25 (0.03–2.21) |
